Search Results
Dec 08, 2025, 09:00 ET DexCom, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before December 26, 2025 to Discuss Your Rights - DXCM
and G7 less reliable than their prior iterations, presenting a material health risk to users relying on those devices for accurate glucose readings; (iii) accordingly, defendants' purported enhancements to the G7, as well as the device's reliability, accuracy, and functionality, were overstated; (iv) defendants
More news about: The Gross Law Firm
Dec 08, 2025, 09:00 ET The Gross Law Firm Reminds Firefly Aerospace Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 12, 2026 - FLY
for its Spacecraft Solutions offerings; (ii) Firefly had overstated the operational readiness and commercial viability of its Alpha rocket program; (iii) the foregoing, once revealed, would likely have a material negative impact on the Company; and (iv) as a result, the offering documents and defendants'
More news about: The Gross Law Firm
Dec 08, 2025, 09:00 ET Abbott's Lingo™ Now on Android™, Expanding Access to Real-Time Glucose Data
people access to real-time glucose data, empowering informed choices that help support better energy, sleep, focus and overall well-being.i ii iii Lingo is for individuals 18 years of age or older and not on insulin who want to make informed decisions about their health. By showing how
More news about: Abbott
Dec 08, 2025, 08:30 ET YY Group Strengthens Leadership Team with Chief Product Officer Role, Appoints Eli Yu to Lead Product Strategy
forward-looking statement. These factors include, but are not limited to, (i) the growth of the hospitality market, (ii) capital and credit market volatility, (iii) local and global economic conditions, (iv) our anticipated growth strategies, (v) governmental approvals and regulations, and (vi) our future business
More news about: YY Group Holding Limited
Dec 08, 2025, 08:30 ET BitMine Immersion (BMNR) Announces ETH Holdings Exceed 3.86 Million Tokens, and Total Crypto and Total Cash Holdings of $13.2 Billion
BitMine remains supported by a premier group of institutional investors including ARK's Cathie Wood, MOZAYYX, Founders Fund, Bill Miller III, Pantera, Kraken, DCG, Galaxy Digital and personal investor Thomas "Tom" Lee to support BitMine's goal of acquiring 5% of ETH
More news about: BitMine Immersion Technologies, Inc.
Dec 08, 2025, 08:30 ET Automotores Gildemeister SpA Announces Early Results and Extension of Early Exchange Time of Previously Announced Exchange Offers by AG Chile Holding II SpA for Outstanding 7.50% Junior Secured Notes due 2027 and 10.00% Subordinated Notes due 2035 and Related Consent Solicitations
$1,000 in value consisting of (i) $970 in principalamount of New2035 Notes and (iii) $30 in cash (1) No representation is made as to the correctness or accuracy of the CUSIP or ISIN numbers
More news about: Automotores Gildemeister SpA
Dec 08, 2025, 08:00 ET Buy It Now, Thank Us Later: Hagerty's 2026 Bull Market List of 11 Appreciation-Ready Enthusiast Cars
go-round had a 2.8-liter, 12-valve, six-cylinder engine under the hood. The 50-and-under crowd represents a whopping 78% of interested buyers for the Mk III GTI.1990–1993 Chevrolet 454 SS ($59,800): Straight-line speed is obviously the animating idea here, but, with an upgraded suspension,
More news about: Hagerty
Dec 08, 2025, 08:00 ET STUB INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that StubHub Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
timing of payments to vendors; (ii) those changes had a significant adverse impact on free cash flow, including trailing 12 months free cash flow; and (iii) as a result, StubHub's free cash flow reports were materially misleading. The quarterly report allegedly revealed that this year-over-year
More news about: Robbins Geller Rudman & Dowd LLP
Dec 08, 2025, 08:00 ET IBM to Acquire Confluent to Create Smart Data Platform for Enterprise Generative AI
Confluent that are forward-looking may include statements regarding: (i) the transaction; (ii) the expected timing of the closing of the transaction; (iii) considerations taken into account in approving and entering into the transaction; (iv) the anticipated benefits to, or impact of, the transaction on
More news about: IBM
Dec 08, 2025, 07:30 ET Contango ORE and Dolly Varden Silver Announce Merger to Create a New North American High-Grade, Mid-Tier Silver & Gold Producer and Developer
project from the underlying owner, CIRI Native Corporation, (ii) a lease on the Lucky Shot project from the underlying owner, Alaska Hardrock Inc., (iii) 100% ownership of approximately 8,600 acres of peripheral State of Alaska mining claims, and (iv) a 100% interest in approximately 145,000 acres of
More news about: Contango Ore
Dec 08, 2025, 07:01 ET Wystawa Blokees na targach CCXP25 w Brazylii: światowa premiera nowego produktu z serii Rycerzy Zodiaku
roku życia.Podczas targów CCXP firma Blokees zaprezentowała również znakomite prace z całego świata, które wzięły udział w sezonie "Fearless" III konkursu BFC CREATION CONTEST 2025. Była to pierwsza okazja do obejrzenia prac BFC z tego sezonu poza internetem, co przyciągnęło uwagę publiczności.
More news about: Blokees
Dec 08, 2025, 04:40 ET Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity or Overweight
gastrointestinal (GI) tolerability of ASC30 titrated weekly was comparable to published results of orforglipron titrated every four weeks in the Phase III ATTAIN-1 study (Table 1). In the ASC30 Phase II study, all GI adverse events (AEs) were grade 1 (mild) and grade 2 (moderate) in severity and mostly
More news about: Ascletis Pharma Inc.
Dec 07, 2025, 20:57 ET IASO Bio Presents Updated Results for Equecabtagene Autoleucel in High-Risk Newly Diagnosed Multiple Myeloma Patients at 2025 ASH
patients had double-hit, and 2 patients had triple-hit cytogenetics. 2 patients had R-ISS stage III with a double-hit, and 1 patient had R-ISS stage III with a triple-hit. 4 patients had extramedullary disease.With a median follow-up of 27.04 months, the median PFS was
More news about: IASO Bio
Dec 07, 2025, 14:00 ET Prologis announces redemption of 3.00% Notes due 2026
local economic and political climates and conditions; (ii) changes in global financial markets, interest rates and foreign currency exchange rates; (iii) increased or unanticipated competition for our properties; (iv) risks associated with acquisitions, dispositions and development of properties, including
More news about: Prologis, Inc.
Dec 07, 2025, 07:30 ET Studies Point to a Growing Role for New Therapies and Immunotherapies in Treating Blood Cancers
inhibitors. This study is the first phase III clinical trial to directly compare a non-covalent BTK inhibitor to a covalent BTK inhibitor in patients with CLL or SLL. It included patients who had not received any previous treatment, a first for any phase III study directly comparing BTK inhibitors, as
More news about: American Society of Hematology
Dec 07, 2025, 01:18 ET All Approved Indications of Five Akeso's Innovative Drugs Included in China's Latest NRDL: Featuring Two First-in-Class Bispecifics with New First-Line Indications and Three Newly Negotiated Drugs
a Phase III head-to-head clinical trial, ivonescimab demonstrated compelling results, reducing the risk of disease progression or death by 49% compared to pembrolizumab. Notably, ivonescimab is the first drug globally to show significantly superior efficacy over pembrolizumab in a Phase III trial. This
More news about: Akeso, Inc.
Dec 07, 2025, 01:09 ET 喜訊！科倫博泰佳泰萊®、達泰萊®、科泰萊®成功納入2025國家基本醫保目錄
NPC的第二項適應症獲批上市，是全球首個獲批一線治療NPC的PD-L1單抗。上述兩項適應症均被納入2025年版國家基本醫保目錄。塔戈利單抗單藥在經二線及以上治療的R/M NPC患者中展現出了良好的療效與安全性，研究結果顯示：截至2022年1月13日，塔戈利單抗單藥治療的ORR為26.5%，中位PFS為2.8個月，中位OS為15.3個月，並且患者整體安全性良好、可控。KL167-Ⅲ-08研究進一步驗證了其在R/M NPC患者一線治療中的臨床應用價值，研究結果顯示：（１）截至2024年2月4日，與化療相比，塔戈利單抗聯合順鉑和吉西他濱一線治療復發或轉移性鼻咽癌可獲得更優的PFS、更高的ORR和更長的DoR，且無論患者PD-L1表達如何，均可獲益；
More news about: 科伦博泰
Dec 06, 2025, 22:40 ET Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List
injection) Product Insert[iii] Limertinib Product Insert
More news about: Innovent Biologics
Dec 06, 2025, 09:30 ET Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma
in CARTITUDE-1 (1% Grade 3 to 4).The most frequent cranial nerve affected was the 7th cranial nerve. Additionally, cranial nerves III, V, and VI have been reported to be affected.Monitor patients for signs and symptoms of cranial nerve palsies. Consider management with systemic
More news about: Johnson & Johnson
Dec 05, 2025, 22:37 ET Six Flags Entertainment Corporation Securities Fraud Class Action Result of Undisclosed Financial Problems and 63% Stock Decline - Investors may Contact Lewis Kahn, Esq, @ KSF
cost-cutting measures, including significant reductions in employee headcount, which materially degraded operational competence and guest experience; (iii) as a result, Legacy Six Flags required a substantial and undisclosed capital infusion to stabilize and revitalize its business, and these acute capital
More news about: Kahn Swick & Foti, LLC
Dec 05, 2025, 22:33 ET Jayud Global Logistics Limited Securities Fraud Class Action Result of Massive Stock Decline - Investors may Contact Lewis Kahn, Esq, @ KSF
(ii) insiders and/or affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign; (iii) the Company's public statements and risk disclosures omitted any mention of the false rumors and artificial trading activity elevating the stock price;
More news about: Kahn Swick & Foti, LLC
Dec 05, 2025, 20:55 ET FLY INVESTOR NOTICE: Firefly Aerospace Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
Spacecraft Solutions offerings; (ii) Firefly Aerospace had overstated the operational readiness and commercial viability of its Alpha rocket program; and (iii) the foregoing, once revealed, would likely have a material negative impact on Firefly Aerospace.The Firefly Aerospace investor class action
More news about: Robbins Geller Rudman & Dowd LLP
Dec 05, 2025, 18:00 ET Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
including negative safety and efficacy findings in future clinical studies (notwithstanding positive findings in earlier preclinical and clinical studies); (iii) rezpegaldesleukin, NKTR-0165, NKTR-0166, NKTR-422 and NKTR-255 are in clinical development and the risk of failure is high and can unexpectedly occur
More news about: Nektar Therapeutics
Dec 05, 2025, 15:30 ET Skye Bioscience, Inc. Class Action: Levi & Korsinsky Reminds Skye Bioscience, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 16, 2026 - SKYE
effective than defendants had led investors to believe; (ii) accordingly, nimacimab's clinical, regulatory, and commercial prospects were overstated; and (iii) as a result, defendants' public statements were materially false and misleading at all relevant times.WHAT'S NEXT? If you suffered a loss
More news about: Levi & Korsinsky, LLP
Dec 05, 2025, 15:30 ET Lost Money on Firefly Aerospace Inc.(FLY)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
for its Spacecraft Solutions offerings; (ii) Firefly had overstated the operational readiness and commercial viability of its Alpha rocket program; (iii) the foregoing, once revealed, would likely have a material negative impact on the Company; and (iv) as a result, the offering documents and defendants'
More news about: Levi & Korsinsky, LLP